Sicart Associates LLC lessened its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 24.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 248,199 shares of the medical instruments supplier’s stock after selling 82,050 shares during the period. OraSure Technologies accounts for about 4.0% of Sicart Associates LLC’s investment portfolio, making the stock its 4th biggest holding. Sicart Associates LLC owned approximately 0.42% of OraSure Technologies worth $5,584,000 as of its most recent filing with the SEC.
A number of other large investors also recently added to or reduced their stakes in OSUR. UBS Asset Management Americas Inc. grew its holdings in OraSure Technologies by 43.5% during the first quarter. UBS Asset Management Americas Inc. now owns 30,996 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 9,400 shares during the period. Wellington Management Group LLP boosted its stake in shares of OraSure Technologies by 0.5% in the first quarter. Wellington Management Group LLP now owns 111,970 shares of the medical instruments supplier’s stock worth $1,448,000 after acquiring an additional 587 shares during the period. Teachers Advisors LLC boosted its stake in shares of OraSure Technologies by 3.0% in the first quarter. Teachers Advisors LLC now owns 781,842 shares of the medical instruments supplier’s stock worth $10,109,000 after acquiring an additional 22,934 shares during the period. Legal & General Group Plc boosted its stake in shares of OraSure Technologies by 591.3% in the first quarter. Legal & General Group Plc now owns 92,139 shares of the medical instruments supplier’s stock worth $1,190,000 after acquiring an additional 78,810 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of OraSure Technologies by 30.3% in the first quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock worth $57,752,000 after acquiring an additional 1,037,439 shares during the period. 92.93% of the stock is owned by institutional investors and hedge funds.
OSUR has been the subject of a number of recent analyst reports. Canaccord Genuity upped their price objective on OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Jefferies Group LLC reaffirmed a “buy” rating and issued a $20.00 price objective on shares of OraSure Technologies in a research note on Tuesday, September 12th. Zacks Investment Research raised OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Saturday, September 9th. Finally, BidaskClub lowered OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $18.21.
In other news, Director Mara G. Aspinall bought 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 7th. The shares were bought at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the transaction, the director now owns 5,000 shares of the company’s stock, valued at $71,150. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Douglas A. Michels sold 22,923 shares of the business’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total value of $527,229.00. The disclosure for this sale can be found here. Insiders sold 61,110 shares of company stock worth $1,362,463 over the last quarter. 6.40% of the stock is owned by company insiders.
OraSure Technologies, Inc. (NASDAQ OSUR) traded up $0.14 during trading hours on Tuesday, hitting $14.39. The company had a trading volume of 904,400 shares, compared to its average volume of 872,066. The stock has a market capitalization of $864.24, a P/E ratio of 27.40, a P/E/G ratio of 2.74 and a beta of 1.39. OraSure Technologies, Inc. has a 12 month low of $8.01 and a 12 month high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. The company had revenue of $42.30 million for the quarter, compared to the consensus estimate of $40.87 million. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The firm’s revenue for the quarter was up 31.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.11 earnings per share. research analysts anticipate that OraSure Technologies, Inc. will post 0.42 EPS for the current year.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.